Eckert & Ziegler Strahlen- und Medizintechnik AG

Legal Proceedings Report • Nov 25, 2022

News Details

Ad-hoc | 25 November 2022 15:36

Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR

Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Study

Eckert & Ziegler Receives Green Light for Phase III Study with PENTIXAFOR

25-Nov-2022 / 15:36 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

---

Berlin, 25 November 2022. PENTIXAPHARM GmbH, a 100% subsidiary of Eckert & Ziegler AG (ISIN DE0005659700, SDAX), received green light from the European Medicines Agency (EMA) to conduct a phase III registration study in patients suffering from various forms of Non-Hodgkin-Lymphomas. Following several rounds of scientific advice, the EMA Committee for Medicinal Products for Human Use (CHMP) endorsed a study design presented by PENTIXAPHARM’s management, which envisions treating up to 500 lymphoma patients with the Gallium-68 based radiotracer PENTIXAFOR in about 30 participating European clinics. In its endorsement the CHMP adopted the advice given by the EMA Scientific Advice Working Party, a multidisciplinary group, which comprises delegates from several national European Health Agencies, members of the Committee for Orphan Medicinal Products, the Paediatric Committee, the Committee for Advanced Therapies and the Pharmacovigilance Risk Assessment Committee. The first treatments with PENTIXAFOR are expected to start in the first half of 2023, subject to approval by national health authorities.

The Executive Board expects to have completed the clinical trials and approval of PENTIXAFOR by the end of 2025 and estimates development costs of EUR 50 million, which will initially be capitalized in the balance sheet and thus not be recognized in the income statement. In addition to the diagnostic agent, Eckert & Ziegler is also developing radiotherapeutics for several hematological indications based on CXCR4 peptides. The Group acquired the global property rights to the CXCR4 receptor addressing agents from the patent licensing office of the Technical University of Munich.

For enquiries please contact:

Eckert & Ziegler AG, Karolin Riehle, Investor Relations

Robert-Rössle-Str. 10, 13125 Berlin, Germany

Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de; www.ezag.com

---

25-Nov-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com

---

Language:	English
Company:	Eckert & Ziegler Strahlen- und Medizintechnik AG
	Robert-Rössle-Str.10
	13125 Berlin
	Germany
Phone:	+49 30 941084-138
Fax:	+49 30 941084-112
E-mail:	karolin.riehle@ezag.de
Internet:	www.ezag.de
ISIN:	DE0005659700
WKN:	565970
Indices:	SDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1497999

End of Announcement	EQS News Service